Curaleaf: Haywood Reiterates $22 Price Target, Names Firm A Top Pick For 2022

On December 28th, Curaleaf Holdings (CSE: CURA) announced that they have entered into a definitive agreement to acquire Bloom Dispensaries for roughly US$211 million in cash, with $50 million being paid at the closing date, and $50/$50/$60 million on the first, second and third anniversary of the closing date. The deal is expected to close in January of 2022 and Curaleaf expects it to be immediately accretive to adjusted EBITA.

Curaleaf currently has 15 analysts covering the stock with an average 12-month price target of C$24.80, or a 135% upside to the current stock price. Out of the 15 analysts, 5 have strong buy ratings, 9 have buy ratings and 1 analyst has a hold rating on the stock. The street high sits at C$31 from Stifel-GMP while the lowest 12-month price target comes in at C$20.

In Haywood Capital Markets’ note, they reiterate their C$22 12-month price target and buy rating, saying that this and the other recently announced acquisitions are an efficient use of proceeds. Bloom Dispensaries operates a 63,500 square foot cultivation and processing facility in Arizona, as well as several dispensaries. Haywood expects that the state of Arizona will do a combined $1.3 billion in sales for 2021.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

Haywood says that Bloom is expected to do roughly $66 million in full-year revenue with adjusted EBITDA margins of >40%, so they have Bloom being acquired at a 3.2x 2021 and 8.0x 2021 revenue and adjusted EBITDA multiple. They also say that Arizona has continued to have a strong medical program while the adult-use program hit a new sales high in October. They believe that the market will grow faster than analysts’ expectations of $760 in adult-use sales by year four, as the state has done roughly $400 million this year alone.

Lastly, Haywood reiterates Curaleaf as their top pick in the cannabis sector, saying that it, “remains well-positioned with the largest state footprint.” They believe that this acquisition and the most recent debt financing will help Curaleaf expand its margins in 2022.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Is Agnico Eagle Seabridge Gold’s Mystery Lender?

This Gold Giant Is Building 1.5 Million More Ounces a Year | Agnico Eagle Q3 Earnings

This Gold Giant Was a Mess. Now It’s Back! | Barrick Mining Q3 2026 Earnings

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Netflix: Q1 2021 Consensus Analyst Estimates

Netflix (NASDAQ: NFLX) will be reporting their first quarter financial results on April 20th after...

Monday, April 19, 2021, 04:10:00 PM

Uber: Analysts Expect Q1 Net Income To Approach Negative $1 Billion

Uber (NYSE: UBER) will be reporting its first quarter financial results today after market close....

Wednesday, May 5, 2021, 02:44:00 PM

PayPal: Analysts Call For Earnings Per Share Of $0.86 For Q2 2022

PayPal Holdings (NASDAQ: PYPL) will be reporting its second quarter financial results today after market...

Tuesday, August 2, 2022, 02:23:00 PM

Numinus Wellness: Eight Capital Initiates With $1.10 Price Target

Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after...

Monday, September 20, 2021, 02:41:00 PM

Plug Power: Canaccord Halves Price Target After Q1 Results

On June 22nd, Plug Power (NASDAQ: PLUG) announced their first-quarter results, The company announced net...

Friday, June 25, 2021, 11:42:00 AM